Mazatrim and Trimethoprim (Mazatrim) combination is used to treat infections such as urinary tract infections, middle ear infections (otitis media), bronchitis, traveler's diarrhea, and shigellosis (bacillary dysentery). Mazatrim and Trimethoprim (Mazatrim) is also used to prevent or treat Pneumocystis jiroveci pneumonia or Pneumocystis carinii pneumonia (PCP), a very serious kind of pneumonia. This type of pneumonia occurs more commonly in patients whose immune systems are not working normally, such as cancer patients, transplant patients, and patients with acquired immune deficiency syndrome (AIDS).
Mazatrim and Trimethoprim (Mazatrim) combination is an antibiotic. It works by eliminating the bacteria that cause many kinds of infections. Mazatrim and Trimethoprim (Mazatrim) will not work for colds, flu, or other virus infections.
Mazatrim and Trimethoprim (Mazatrim) is available only with your doctor's prescription.
Mazatrim indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Mazatrim and other antibacterial drugs, Mazatrim should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Urinary Tract Infections
For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.
Acute Otitis Media
For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when, in the judgment of the physician, Mazatrim offers some advantage over the use of other antimicrobial agents. To date, there is limited data on the safety of repeated use of Mazatrim in pediatric patients under two years of age. Mazatrim is not indicated for prophylactic or prolonged administration in otitis media at any age.
Acute Exacerbations of Chronic Bronchitis in Adults
For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when, a physician deems that, Mazatrim could offer some advantage over the use of a single antimicrobial agent.
Travelers' Diarrhea in Adults
For the treatment of travelers' diarrhea due to susceptible strains of enterotoxigenic E. coli.
Shigellosis
For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated.
Pneumocystis jiroveci Pneumonia
For the treatment of documented Pneumocystis jiroveci pneumonia. For prophylaxis against Pneumocystis jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis jiroveci pneumonia.
How should I use Mazatrim?
Use Mazatrim suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Take Mazatrim suspension by mouth with or without food.
Shake well before each use.
Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
Mazatrim suspension works best if it is taken at the same time(s) each day.
Take Mazatrim suspension with a full glass of water (8 oz [240 mL]). Drinking extra fluids while you are taking Mazatrim suspension is recommended. Check with your doctor for instructions.
To clear up your infection completely, take Mazatrim suspension for the full course of treatment. Keep taking it even if you feel better in a few days.
If you are using Mazatrim suspension to prevent an infection, continue to take it even if you feel well. Do not miss any doses.
If you miss a dose of Mazatrim suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Mazatrim suspension.
Uses of Mazatrim in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Oral: Treatment of urinary tract infections (UTIs) due to
Escherichia coli, Klebsiella and Enterobacter spp, Morganella morganii, Proteus mirabilis, and Proteus vulgaris; acute otitis media; acute exacerbations of chronic obstructive pulmonary disease due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae; treatment and prophylaxis of Pneumocystis pneumonia (PCP); traveler's diarrhea due to enterotoxigenic E. coli; treatment of shigellosis caused by Shigella flexneri or Shigella sonnei.
IV: Treatment of PCP; treatment of shigellosis caused by S. flexneri or S. sonnei; treatment of severe or complicated UTIs due to E. coli, Klebsiella and Enterobacter spp, M. morganii, P. mirabilis, and P. vulgaris.
Off Label Uses
Bite wound infection, prophylaxis or treatment (animal or human bite)
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), Mazatrim, in combination with an appropriate agent for anaerobic coverage, is an effective and recommended alternative for the prophylaxis and treatment of animal bite wounds.
Clinical experience suggests the utility of Mazatrim as an alternative agent for the prophylaxis and treatment of human bite wounds.
Toxoplasma gondii encephalitis (prophylaxis/treatment/chronic maintenance) in HIV-infected patients
Based on the US Department of Health and Human Services (HHS) guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, Mazatrim is an effective and recommended agent for primary prophylaxis of Toxoplasma gondii encephalitis and is an effective and recommended alternative agent for the treatment of or as chronic maintenance therapy of T. gondii encephalitis in HIV-infected patients.
Mazatrim description
sponsored
A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the Trimethoprim (Mazatrim)-Mazatrim combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim (Mazatrim) resistance has been reported.
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Contraindicated in pediatric patients less than 2 months of age.
Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients and Acute Otitis Media in Pediatric Patients:
Adults: The usual adult dosage in the treatment of urinary tract infections is one Mazatrim DS (double strength) tablet, two Mazatrim tablets, or four teaspoonfuls (20 mL) Mazatrim Suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.
Pediatric Patients: The recommended dose for pediatric patients with urinary tract infections or acute otitis media is 8 mg/kg Trimethoprim (Mazatrim) and 40 mg/kg Mazatrim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this
Dosage:
Pediatric Patients: Two Months of Age or Older
Weight
Dose-Every 12 Hours
lb
kg
Teaspoonfuls
Tablets
22
10
1 (5 mL)
44
20
2 (10 mL)
1
66
30
3 (15 mL)
1 1/2
88
40
4 (20 mL)
2 (or 1 DS Tablet)
For Patients With Impaired Renal Function: When renal function is impaired, a reduced dosage should be employed using the following table:
Creatinine
Recommended
Clearance
Dosage
(mL/min)
Regimen
Above 30
Use Standard Regimen
15-30
1/2 the Usual Regimen
Below 15
Use Not Recommended
Acute Exacerbations of Chronic Bronchitis in Adults:
The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is one Mazatrim DS (double strength) tablet, two Mazatrim tablets, or four teaspoonfuls (20 mL) Mazatrim Suspension every 12 hours for 14 days.
Travelers' Diarrhea in Adults:
For the treatment of travelers' diarrhea, the usual adult dosage is one Mazatrim DS (double strength) tablet, two Mazatrim tablets, or four teaspoonfuls (20 mL) of Mazatrim Suspension every 12 hours for 5 days.
Pneumocystis Carinii Pneumonia:
Treatment:
Adults and Pediatric Patients: The recommended dosage for treatment of patients with documented Pneumocystis carinii pneumonia is 15 to 20 mg/kg Trimethoprim (Mazatrim) and 75 to 100 mg/kg Mazatrim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. The following table is a guideline for the upper limit of this
Dosage:
Weight Dose – Every 6 Hours
lb
kg
Teaspoonfuls
Tablets
18
8
1 (5 mL)
35
16
2 (10 mL)
1
53
24
3 (15 mL)
1 1⁄2
70
32
4 (20 mL)
2 (or 1 DS Tablet)
88
40
5 (25 mL)
2 1⁄2
106
48
6 (30 mL)
3 (or 1 1⁄2 DS Tablets)
141
64
8 (40 mL)
4 (or 2 DS Tablets)
176
80
10 (50 mL)
5 (or 2 1⁄2 DS Tablets)
For the lower limit dose (15 mg/kg Trimethoprim (Mazatrim) and 75 mg/kg Mazatrim per 24 hours) administer 75% of the dose in the above table.
Prophylaxis:
Adults: The recommended dosage for prophylaxis in adults is one Mazatrim DS (double strength) tablet daily.
Pediatric Patients: For pediatric patients, the recommended dose is 150 mg/m2/day Trimethoprim (Mazatrim) with 750 mg/m2/day Mazatrim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 320 mg Trimethoprim (Mazatrim) and 1,600 mg Mazatrim. The following table is a guideline for the attainment of this dosage in pediatric patients:
Body Surface Area Dose–every 12 hours
(m2)
Teaspoonfuls
Tablets
0.26
1⁄2 (2.5 mL)
0.53
1 (5 mL)
1⁄2
1.06
2 (10 mL)
1
More about Mazatrim (Mazatrim / Trimethoprim (Mazatrim))
Side Effects
During Pregnancy
Dosage Information
Drug Interactions
Support Group
14 Reviews - Add your own review/rating
Generic Availability
Consumer resources
Mazatrim
Mazatrim Suspension
Mazatrim (Advanced Reading)
Mazatrim Pediatric Suspension (Advanced Reading)
Other brands: Mazatrim, Mazatrim DS, SMZ-TMP DS, Sulfatrim, More (2) »
Trimethoprim (Mazatrim) is an inhibitor of CYP2C8 as well as OCT2 transporter. Mazatrim is an inhibitor of CYP2C9. Caution is recommended when Mazatrim is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2.
In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.
It has been reported that Mazatrim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when Mazatrim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.
Mazatrim may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). Mazatrim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.
Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.
There have been reports of marked but reversible nephrotoxicity with coadministration of Mazatrim and cyclosporine in renal transplant recipients.
Increased digoxin blood levels can occur with concomitant Mazatrim therapy, especially in elderly patients. Serum digoxin levels should be monitored.
Increased Mazatrim blood levels may occur in patients who are also receiving indomethacin.
Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding 25 mg weekly may develop megaloblastic anemia if Mazatrim is prescribed.
The efficacy of tricyclic antidepressants can decrease when coadministered with Mazatrim.
Mazatrim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Additional monitoring of blood glucose may be warranted.
In the literature, a single case of toxic delirium has been reported after concomitant intake of Mazatrim and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.
In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of Mazatrim and an angiotensin converting enzyme inhibitor.
Drug/Laboratory Test Interactions
Mazatrim, specifically the Trimethoprim (Mazatrim) component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).
The presence of Mazatrim and Trimethoprim (Mazatrim) may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.
The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA, OTHER BLOOD DYSCRASIAS, AND HYPERSENSITIVITY OF THE RESPIRATORY TRACT.
The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides), and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. Diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides.
Musculoskeletal:
Arthralgia and myalgia. Isolated cases of rhabdomyolosis have been reported with Mazatrim, mainly in AIDS patients.
Respiratory System:
Cough, shortness of breath, and pulmonary infiltrates.
Mazatrim and Trimethoprim (Mazatrim) is contraindicated in patients with a known hypersensitivity to Trimethoprim (Mazatrim), USP or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of Trimethoprim (Mazatrim), USP and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency.
Mazatrim and Trimethoprim (Mazatrim) is contraindicated in pediatric patients less than 2 months of age. Mazatrim and Trimethoprim (Mazatrim) is also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored.
DailyMed. "SULFAMETHOXAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
DailyMed. "POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Mazatrim are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mazatrim. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
